References
Agusti A, Bel E, Thomas M, Vogelmeier C, Brusselle G, Holgate S, et al. (2016). Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J 47: 410-419.
Bagnasco D, Ferrando M, Varricchi G, Puggioni F, Passalacqua G, & Canonica GW (2017). Anti-Interleukin 5 (IL-5) and IL-5Ra Biological Drugs: Efficacy, Safety, and Future Perspectives in Severe Eosinophilic Asthma. Frontiers in medicine 4: 135.
Bandeira-Melo C, Bozza PT, & Weller PF (2002). The cellular biology of eosinophil eicosanoid formation and function. J Allergy Clin Immunol 109: 393-400.
Bel EH, & Ten Brinke A (2017). New Anti-Eosinophil Drugs for Asthma and COPD: Targeting the Trait! Chest 152: 1276-1282.
Berger P, Scotto-Gomez E, Molimard M, Marthan R, Le Gros V, & Tunon-de-Lara JM (2007). Omalizumab decreases nonspecific airway hyperresponsiveness in vitro. Allergy 62: 154-161.
Black JL, Panettieri RA, Jr., Banerjee A, & Berger P (2012). Airway smooth muscle in asthma: just a target for bronchodilation? Clin Chest Med 33: 543-558.
Bleecker ER, FitzGerald JM, Chanez P, Papi A, Weinstein SF, Barker P, et al. (2016). Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial. Lancet 388:2115-2127.
Borish L (2016). The immunology of asthma: asthma phenotypes and their implications for personalized treatment. Annals of Allergy, Asthma & Immunology 117: 108-114.
Calzetta L, Matera MG, & Cazzola M (2018a). Pharmacological mechanisms leading to synergy in fixed-dose dual bronchodilator therapy. Curr Opin Pharmacol 40: 95-103.
Calzetta L, Matera MG, Facciolo F, Cazzola M, & Rogliani P (2018b). Beclomethasone dipropionate and formoterol fumarate synergistically interact in hyperresponsive medium bronchi and small airways. Respiratory research 19: 65.
Cazzola M, Calzetta L, Page CP, Rinaldi B, Capuano A, & Matera MG (2011). Protein prenylation contributes to the effects of LPS on EFS-induced responses in human isolated bronchi. Am J Respir Cell Mol Biol 45: 704-710.
Cazzola M, Calzetta L, Puxeddu E, Ora J, Facciolo F, Rogliani P, et al. (2016a). Pharmacological characterisation of the interaction between glycopyrronium bromide and indacaterol fumarate in human isolated bronchi, small airways and bronchial epithelial cells. Respiratory research 17: 70.
Cazzola M, Calzetta L, Rogliani P, Puxeddu E, Facciolo F, & Matera MG (2016b). Interaction between corticosteroids and muscarinic antagonists in human airways. Pulmonary pharmacology & therapeutics 36:1-9.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz MA, et al. (2018). Experimental design and analysis and their reporting II: updated and simplified guidance for authors and peer reviewers. British journal of pharmacology 175: 987-993.
Damera G, & Panettieri J, Reynold A (2011). Does airway smooth muscle express an inflammatory phenotype in asthma? British journal of pharmacology 163: 68-80.
Drake MG, Lebold KM, Roth-Carter QR, Pincus AB, Blum ED, Proskocil BJ, et al. (2018). Eosinophil and airway nerve interactions in asthma. J Leukoc Biol 104: 61-67.
Eum S-Y, Maghni K, Tolloczko B, Eidelman DH, & Martin JG (2005). IL-13 may mediate allergen-induced hyperresponsiveness independently of IL-5 or eotaxin by effects on airway smooth muscle. American Journal of Physiology-Lung Cellular and Molecular Physiology 288:L576-L584.
European Medicines Agency (2015). Nucala - EMEA/H/C/003860 - N/0027. Available athttps://www.ema.europa.eu/en/documents/product-information/nucala-epar-product-information_en.pdfLast accessed March 21, 2020.
European Medicines Agency (2018). Fasenra - EMEA/H/C/004433 - II/0014/G. Available athttps://www.ema.europa.eu/en/documents/product-information/fasenra-epar-product-information_en.pdf. Last accessed March 21, 2020.
Farne HA, Wilson A, Powell C, Bax L, & Milan SJ (2017). Anti-IL5 therapies for asthma. Cochrane Database Syst Rev 9: CD010834.
Faul JL, Tormey VJ, Leonard C, Burke CM, Farmer J, Horne SJ, et al. (1997). Lung immunopathology in cases of sudden asthma death. Eur Respir J 10: 301-307.
FitzGerald JM, Bleecker ER, Nair P, Korn S, Ohta K, Lommatzsch M, et al. (2016). Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 388: 2128-2141.
Flood-Page P, Swenson C, Faiferman I, Matthews J, Williams M, Brannick L, et al. (2007). A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am J Respir Crit Care Med 176: 1062-1071.
GINA (2019). Global Initiative for Asthma (GINA). Global strategy for asthma management and prevention. Available at:https://ginasthma.org/wp-content/uploads/2019/06/GINA-2019-main-report-June-2019-wms.pdf. Last accessed April 2, 2020.
Gounni AS, Wellemans V, Yang J, Bellesort F, Kassiri K, Gangloff S, et al. (2005). Human airway smooth muscle cells express the high affinity receptor for IgE (FcεRI): a critical role of FcεRI in human airway smooth muscle cell function. The Journal of Immunology 175: 2613-2621.
Grunstein MM, Hakonarson H, Leiter J, Chen M, Whelan R, Grunstein JS, et al. (2002). IL-13-dependent autocrine signaling mediates altered responsiveness of IgE-sensitized airway smooth muscle. Am J Physiol Lung Cell Mol Physiol 282: L520-528.
Hakonarson H, Maskeri N, Carter C, Chuang S, & Grunstein MM (1999a). Autocrine interaction between IL-5 and IL-1β mediates altered responsiveness of atopic asthmatic sensitized airway smooth muscle. The Journal of clinical investigation 104: 657-667.
Hakonarson H, Maskeri N, Carter C, & Grunstein MM (1999b). Regulation of TH1- and TH2-type cytokine expression and action in atopic asthmatic sensitized airway smooth muscle. J Clin Invest 103: 1077-1087.
Haldar P, Brightling CE, Hargadon B, Gupta S, Monteiro W, Sousa A, et al. (2009). Mepolizumab and exacerbations of refractory eosinophilic asthma. N Engl J Med 360: 973-984.
Hamelmann E, Oshiba A, Loader J, Larsen GL, Gleich G, Lee J, et al. (1997). Antiinterleukin-5 antibody prevents airway hyperresponsiveness in a murine model of airway sensitization. Am J Respir Crit Care Med 155: 819-825.
Head ML, Holman L, Lanfear R, Kahn AT, & Jennions MD (2015). The extent and consequences of p-hacking in science. PLoS Biol 13:e1002106.
Hyde DM, Hamid Q, & Irvin CG (2009). Anatomy, pathology, and physiology of the tracheobronchial tree: emphasis on the distal airways. J Allergy Clin Immunol 124: S72-77.
Ichinose M, Miura M, Tomaki M, Oyake T, Kageyama N, Ikarashi Y, et al. (1996). Incubation with IgE increases cholinergic neurotransmission in human airways in vitro. Am J Respir Crit Care Med 154:1272-1276.
Kolbeck R, Kozhich A, Koike M, Peng L, Andersson CK, Damschroder MM, et al. (2010). MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol 125: 1344-1353 e1342.
Leckie MJ, ten Brinke A, Khan J, Diamant Z, O’Connor BJ, Walls CM, et al. (2000). Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356: 2144-2148.
Liccardi G, Salzillo A, Calzetta L, Cazzola M, Matera MG, & Rogliani P (2016). Can bronchial asthma with an highly prevalent airway (and systemic) vagal tone be considered an independent asthma phenotype? Possible role of anticholinergics. Respiratory medicine 117:150-153.
Manson ML, Säfholm J, James A, Johnsson A-K, Bergman P, Al-Ameri M, et al. (2019). IL-13 and IL-4, but not IL-5 nor IL-17A, induce hyperresponsiveness in isolated human small airways. Journal of Allergy and Clinical Immunology.
Martin UJ, Fuhr R, Forte P, Barker P, Axley MJ, Aurivillius M, et al. (2019). Comparison of autoinjector with accessorized prefilled syringe for benralizumab pharmacokinetic exposure: AMES trial results. Journal of Asthma: 1-9.
Mathur M, Herrmann K, Li X, Qin Y, Weinstock J, Elliott D, et al.(1999). TRFK-5 reverses established airway eosinophilia but not established hyperresponsiveness in a murine model of chronic asthma. Am J Respir Crit Care Med 159: 580-587.
Mauser PJ, Pitman AM, Fernandez X, Foran SK, Adams GK, 3rd, Kreutner W, et al. (1995). Effects of an antibody to interleukin-5 in a monkey model of asthma. Am J Respir Crit Care Med 152: 467-472.
Mitchell RW, Ndukuw IM, Ikeda K, Arbetter K, & Leff AR (1993). Effect of immune sensitization on stimulated ACh release from trachealis muscle in vitro. The American journal of physiology 265: L13-18.
Mitchell RW, Rabe KF, Magnussen H, & Leff AR (1997). Passive sensitization of human airways induces myogenic contractile responses in vitro. J Appl Physiol (1985) 83: 1276-1281.
Molfino NA, Gossage D, Kolbeck R, Parker JM, & Geba GP (2012). Molecular and clinical rationale for therapeutic targeting of interleukin-5 and its receptor. Clin Exp Allergy 42: 712-737.
Mukherjee M, Sehmi R, & Nair P (2014). Anti-IL5 therapy for asthma and beyond. World Allergy Organ J 7: 32.
Nag SS, Xu LJ, Hamid Q, & Renzi PM (2003). The effects of IL-5 on airway physiology and inflammation in rats. Journal of allergy and clinical immunology 111: 558-566.
Nair P, Wenzel S, Rabe KF, Bourdin A, Lugogo NL, Kuna P, et al.(2017). Oral Glucocorticoid-Sparing Effect of Benralizumab in Severe Asthma. The New England journal of medicine 376: 2448-2458.
Ortega HG, Liu MC, Pavord ID, Brusselle GG, FitzGerald JM, Chetta A, et al. (2014). Mepolizumab treatment in patients with severe eosinophilic asthma. N Engl J Med 371: 1198-1207.
Pavord ID, Beasley R, Agusti A, Anderson GP, Bel E, Brusselle G, et al. (2018). After asthma: redefining airways diseases. Lancet 391: 350-400.
Pavord ID, Korn S, Howarth P, Bleecker ER, Buhl R, Keene ON, et al. (2012). Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial. Lancet 380: 651-659.
Rabe KF (1998). Mechanisms of immune sensitization of human bronchus. Am J Respir Crit Care Med 158: S161-170.
Rogliani P, Calzetta L, Capuani B, Facciolo F, Cazzola M, Lauro D, et al. (2016). Glucagon-Like Peptide 1 Receptor: A Novel Pharmacological Target for Treating Human Bronchial Hyperresponsiveness. Am J Respir Cell Mol Biol 55: 804-814.
Rogliani P, Matera MG, Facciolo F, Page C, Cazzola M, & Calzetta L (2020). Beclomethasone dipropionate, formoterol fumarate and glycopyrronium bromide: Synergy of triple combination therapy on human airway smooth muscle ex vivo. Br J Pharmacol 177: 1150-1163.
Schaafsma D, Zuidhof AB, Nelemans SA, Zaagsma J, & Meurs H (2006). Inhibition of Rho-kinase normalizes nonspecific hyperresponsiveness in passively sensitized airway smooth muscle preparations. Eur J Pharmacol 531: 145-150.
Schmidt D, & Rabe KF (2000). Immune mechanisms of smooth muscle hyperreactivity in asthma. J Allergy Clin Immunol 105: 673-682.
Schmidt D, Ruehlmann E, Branscheid D, Magnussen H, & Rabe KF (1999). Passive sensitization of human airways increases responsiveness to leukotriene C4. Eur Respir J 14: 315-319.
Shabbir S, Pouliquen IJ, Bentley JH, Bradford ES, C. Kaisermann M, & Albayaty M (2019). The pharmacokinetics and relative bioavailability of mepolizumab 100 mg liquid formulation administered subcutaneously to healthy participants: a randomized trial. Clinical Pharmacology in Drug Development.
Shardonofsky FR, Venzor J, 3rd, Barrios R, Leong KP, & Huston DP (1999). Therapeutic efficacy of an anti-IL-5 monoclonal antibody delivered into the respiratory tract in a murine model of asthma. J Allergy Clin Immunol 104: 215-221.
Tanaka H, Nagai H, & Maeda Y (1998). Effect of anti-IL-4 and anti-IL-5 antibodies on allergic airway hyperresponsiveness in mice. Life Sci 62: PL169-174.
NUCALA (mepolizumab) for injection, for subcutaneous use. Available at https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/125526s004lbl.pdf. Last accessed March 21, 2020. [Online] [Accessed].
Fasenra (benralizumab) 30 mg/mL Injection. Available at https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/761070Orig1s000TOC.cfm. Last accessed March 21, 2020. [Online] [Accessed].